Evidence supporting the use of: Soy isoflavones
For the health condition: Arteriosclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Soy isoflavones, which are phytoestrogens found in soybeans, have been investigated for their potential cardiovascular benefits, including their role in supporting or treating arteriosclerosis (the thickening and hardening of artery walls). Several observational studies and small clinical trials suggest that soy isoflavones may have a modest effect on cardiovascular health. The mechanisms are believed to involve the improvement of endothelial function, antioxidant effects, and anti-inflammatory actions. Isoflavones may help reduce LDL cholesterol and improve arterial elasticity, both of which are relevant to the prevention of arteriosclerosis. For instance, a meta-analysis published in Atherosclerosis in 2012 indicated minor improvements in arterial stiffness with soy isoflavone supplementation. However, the overall quality of evidence is limited by small sample sizes, short durations, and inconsistent results across studies. Guidelines from major cardiovascular societies do not currently recommend soy isoflavones as a primary therapy for arteriosclerosis. In summary, while there is some scientific interest and preliminary evidence supporting a possible benefit, the strength of the evidence is modest (rated 2 out of 5), and more large, well-controlled clinical trials are needed to establish efficacy and optimal dosing.

More about soy isoflavones
More about Arteriosclerosis